

# **Big Data and IBM Watson**

Making a Market, Making a Difference



© 2012 International Business Machines Corporation



#### Topics

- What is Big Data and why does it matter?
- How does IBM Watson leverage Big Data Analytics in Healthcare?
- What are some of the early results from Watson customers?



Four years ago, we started working with organizations to build a smarter planet.

Through thousands of client engagements, we learned that analytics is fundamental to success.



<u>WATSON</u>

## Data is the rapidly becoming the foundation for a Smarter Planet





#### Outperformers are capitalizing on the opportunity



Source: IBM CEO Study, 2012. Q22 "How good is your organization at driving value from data? [Today]" (n=631 to 636

#### CIOs are turning to innovative technologies to deliver outcomes

#### Technologies for innovation and solving specific business challenges







# **Big Data: Think beyond the traditional data types**



Volume
Structured
Throughput

- Velocity
  Semi-structured
  Ingestion
- Variety
  Highly unstructured
  Veracity
- Variety
  Highly unstructured
  Volume



8

WATSON

## **Big Data is characterized by the 'Four Vs'**



\* Truthfulness, accuracy or precision, correctness

<u>WATSON</u>

#### Big data creates more opportunities for analytics

Gain more complete answers Extend existing analytics to provide additional insights

#### **Reduce IT Costs**

Rethink existing approaches to how data and content is managed, stored and analyzed to reduce infrastructure costs Using information and analytics in new ways and exciting ways

# Create new perspectives

Extend analytics to communities and processes not reached before

#### Uncover new business opportunities

Identify new offerings and new business models that create value

Web & Social<br/>Interaction DataImage: Content bataImage: Content bata</tr



# Healthcare industry is beset with some of the most complex information challenges we collectively face



Medical information is doubling every 5 years, much of which is unstructured

81% of physicians

report spending 5

hours or less per

medical journals

month reading



1 in 5

diagnosis that are estimated to be inaccurate or incomplete

# 1.5 million

errors in the way medications are prescribed, delivered and taken in the U.S. every year



# 44,000 -98,000

# of Americans who die each year from preventable medical errors in hospitals alone



#### Topics

- What is Big Data and why does Big Data Analytics matter?
- How does IBM Watson leverage Big Data Analytics in Healthcare?
- What are some of the early results from Watson customers?









## **Brief History of IBM Watson**



#### Why Watson for healthcare?

Policy

hanges

- Diagnosis and treatment errors
- Shortage of MDs
- Demand for remote medicine

Complexity

- Shift from Fee-for-Service to ACOs
- Focus on Wellness and Prevention
- Universal coverage

Evidence-based Medicine



Personalized Medicine

#### Info Overload

- Medical data doubles every 5 years
- Detailed patient biomedical markers
- Targeted therapies

 Costs are 18% of US GDP
 24% of #2.27 H0

Costs

- 34% of \$2.3T US spend is waste
- Costs can vary up to 10x



#### Why Cancer Care Solutions?

cancer

in the US in 2010



15-18% / yr.

receive the wrong diagnosis initially



#### Businesses are "dying of thirst in an ocean of data"



1 in 2

business leaders don't have access to data they need 83%

of CIOs cited BI and analytics as part of their visionary plan 2.2X more likely that top performers use business analytics

## Why is it so hard for computers to understand us?



- Noses that run and feet that smell?
- How can a house burn up as it burns down?
- Does CPD represent a complex comorbidity of lung cancer?
- What mix of zero-coupon, non-callable, A+ munis fit my risk tolerance?



#### IBM Watson combines transformational technologies



<u>WATSON</u>

# How Watson Works: DeepQA Architecture





# Putting the pieces together at point of impact can be game changing



## Watson enables three classes of cognitive services



#### Ask

- Leverage vast amounts of data
- Ask questions for greater insights
- Natural language inquiries
- e.g. Next generation Chat

ise Comp	arison versus lop 2 Sugg		
	Selected Treatment Plerixafor+Sorafenib	Top. Decit.	
Population Evaluated	5	15	
ted Survival Months	29	21	
Weighted Attributes	Blast ANC WBC FLT3+ Diabetes	Blast Platelets WBC FLT3+ Diabetes	
cted Response	PR	PR	
ponses for Cohorts - S	elected Treatment		
Comorbidity	Prior Cancer Oytog Patient Description	enetics	

#### Discover

- Find the rationale for given answers
- Prompt for inputs to yield improved responses
- Inspire considerations of new ideas
- e.g. Next generation Search → Discovery



#### Decide

- Ingest and analyze domain sources, info models
- Generate evidence based decisions with confidence
- Learn with new outcomes and actions
- e.g. Next generation Apps → Probabilistic Apps



#### Putting Watson to work in healthcare





#### **Smarter Care – We have the capabilities to deliver**



- · Extends health with social determinants to provide a holistic view of an individual
- Focuses on high cost, high need and high risk individuals
- Enables collaboration in a complex ecosystem aimed at improving outcomes

## Topics

- What is Big Data and why does Big Data Analytics matter?
- How does IBM Watson leverage Big Data Analytics in Healthcare?
- What are some of the early results from Watson customers?



#### Watson for healthcare 2013

Vision	TEACH	PRACTICE		PAY	
	Future Solutions	Cancer Solutions (2)		Engagement Solutions (2)	
Offering	Teaching Solutions	Oncology Research Advisor	Oncology Diagnosis & Treatment Advisor	Virtual Care Management Advisor ( <i>Concept</i> )	Utilization Mgmt/ Authorization Advisor
Users	Educators Students Consumers	Cancer Research Institutions	All Cancer Care Centers	Payers and large Providers	BC/BS payers Other payers
Value	Improve medical education Educate and engage patients	Accelerate discovery of treatments and time to widespread adoption	Improve patient outcomes and efficiencies Share best practices	Improve adherence to on-going treatment and wellness	Streamline authorization
Next Steps	1. US MLE 2. Research	<ol> <li>Production solutions</li> <li>Expansion to additional diseases</li> </ol>	<ol> <li>Successful Pilots</li> <li>Integration into broader care management workflows</li> </ol>	<ol> <li>Scalable solution</li> <li>Successful Pilots</li> </ol>	<ol> <li>Ramped production</li> <li>Adoption outside WellPoint</li> </ol>



## Today Watson is helping payers streamline pre-approvals

#### THEN

Written authorization / subjective assessment / slow response

#### NEXT

Fact based – data driven analysis / systematic review & recommendation / timely response

#### NOW

Manual review / preapproval / code based procedures / guideline driven



### **NEJM** medical concept annotations



# VIDEO

# Watson at Work in Healthcare





#### Watson is helping improve how medicine is practiced

#### THEN

Paper based files / limited knowledge sharing / experience based decisions

#### NOW

Electronic medical records / information overload / 55% medicine evidence based

#### NEXT

Real time insights / full transparency / confidence weighted actions





Watson goes to work to help researchers as well

# Accelerate Time to Clinical Insights

# Improve Decisions and Outcomes



**Ultimate Goal: Become the Most Essential Company** 

#### IBM Oncology Diagnosis and Treatment Advisor

Shows how Watson can assist an Oncologist by:

- Synthesizing disparate data patient records, clinician notes, test results, pathology reports, etc.
- Identifying missing pieces of data recommending tests with complete transparency
- Suggesting personalized, confidenceweighted, evidence-based options to improve quality of care and patient experience



# DEMONSTRATION

## Watson Research & Insight Advisor

Provides research oncologists the ability to:

- Dynamically build a patient cohort
- Suggest confidence-weighted treatment options for that cohort
- Generate insights on cohort trends from clinical, medical, and patient data
- Accelerate treatment identification, publication and distribution

	N. Evidence				
Plantxafor+Sorafanib Diver operating combination Oner operating and Determine effective when add Databases, Prima effective and Databases, Prima beforced this cover esponse Determines sower esponse	ofFLT3 + and Diabeten, Pinkie evere evaluated given its ng pagent activation of every evaluated given its ng pagent activation of pagent activation of the pagent activation of the evaluation of the second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second	Minimum path ator-Soratenio soems to response sor PLT3 - sob response tor PLT3 - sob response tor PLT3 - sol response to patholic solution atoria response. Atolice a biocchemic al makeup of	ent population = 50 be the best choice ents, but seem less ent bis combination in Blood hus la Baberd explaining	Clinical Data Key weights from clinical data For postwate but are diabetic and Fills, then	
Patient Population Evaluated	Selected Treatment : Plerixafor+Sorafenib	d Treatment : afor+Sorafenib Decilibine		Decibbine has a high incidence of response for Leukemia nation (45% with n=1400)	ir resp
Top 5 Weighted Attributes	29 Blast	15 21	Azacitidine 25	Decisione expected response grops if the patient is diabeted (24% with n = 15)	ârię
Expected Response Confidence in Response	ANC WBC FLT3+ Disabotes PR	Blast Platelets WBC FLT3+ Disbotco	Blast ANC WBC FLT3+ Diabetes	Literature References	
Responses for Cohorts -	Selected Treatment	PR 88%	PR 78%	Response rates using International Working Group data Response areas using International Working Group data (Astron 4 2520) Birth	
Filters Concrtidity	Prior Cancer		Piter	View -> Rate Relevance Dr. Rate Relevance	tients
Complete Remission:	orafenib # of Pat	ients		Novamber 17, 2008 View ->	1 22 1
HLE.	2	26 M	atage	NCCN Practice Guidelines: Myelodwaniantice Relevance	r alta i
Hi-P;	2	30%		Clinician Clinic	1.00
HLN.	5	10%		- Hucian Feedback	
Stable Disease:	2	25%		Dr. Smith - 10:14.888 11/12/12 This treatment with 11/12/12	
Testa Progression:	2	10%		white blood cell counts. May been where the part	
Focal Patients Evaluated	2	10%		Dr. Richter, 1000 Dr. Richter,	95 rea
	50	10%		One of my diabetic patients had a snike in recommond cloper model as a snike in about the snike in the snik	etes àr

uncernalities as soon as possible to possibly adjust therapy , Murray, 1000ms and

# DEMONSTRATION



# How it Works: Cloud Delivery and Outcome Based Pricing



#### How it Works: Watson healthcare architecture



### **Getting Started with Watson**





# How it Works: Watson Products and Infrastructure







# Watson is ushering in a new era of computing . . .



...enabling new opportunities and outcomes in healthcare

# Thank you!





#### Please note

IBM's statements regarding its plans, directions, and intent are subject to change or withdrawal without notice at IBM's sole discretion.

Information regarding potential future products is intended to outline our general product direction and it should not be relied on in making a purchasing decision.

The information mentioned regarding potential future products is not a commitment, promise, or legal obligation to deliver any material, code or functionality. Information about potential future products may not be incorporated into any contract. The development, release, and timing of any future features or functionality described for our products remains at our sole discretion.

Performance is based on measurements and projections using standard IBM benchmarks in a controlled environment. The actual throughput or performance that any user will experience will vary depending upon many factors, including considerations such as the amount of multiprogramming in the user's job stream, the I/O configuration, the storage configuration, and the workload processed. Therefore, no assurance can be given that an individual user will achieve results similar to those stated here.